2-[5-(5-Carbamimidoyl-1H-benzoimidazol-2-yl)-6-(2-methoxy-ethoxymethoxy)-3'-nitro-biphenyl-3-yl]-succinic acid dimethyl ester | 878674-44-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-[5-(5-Carbamimidoyl-1H-benzoimidazol-2-yl)-6-(2-methoxy-ethoxymethoxy)-3'-nitro-biphenyl-3-yl]-succinic acid dimethyl ester
• CAS: 878674-44-3
• 化学式: C₃₀H₃₁N₅O₉
• 分子量: 605.604
• InChiKey: SBPCCJGTACZSMZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.91
• 重原子数：
  44.0
• 可旋转键数：
  14.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  201.98
• 氢给体数：
  3.0
• 氢受体数：
  11.0

反应信息

• 作为反应物：
  描述：

  2-[5-(5-Carbamimidoyl-1H-benzoimidazol-2-yl)-6-(2-methoxy-ethoxymethoxy)-3'-nitro-biphenyl-3-yl]-succinic acid dimethyl ester 在 盐酸 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 1.0h， 生成 2-[5-(5-Carbamimidoyl-1H-benzoimidazol-2-yl)-6-hydroxy-3'-nitro-biphenyl-3-yl]-succinic acid dimethyl ester
  参考文献：
  名称：

  Factor VIIa inhibitors: Gaining selectivity within the trypsin family

  摘要：

  Within the trypsin family of coagulation proteases, obtaining highly selective inhibitors of factor VIIa has been challenging. We report a series of factor Vila (fVIIa) inhibitors based on the 5-amidino-2-(2-hydroxy-biphenyl-3-yl)-benzimidazole (1) scaffold with potency for fVIIa and high selectivity against factors IIa, Xa, and trypsin. With this scaffold class, we propose that a unique hydrogen bond interaction between a hydroxyl on the distal ring of the biaryl system and the backbone carbonyl of fVIIa lysine-192 provides a basis for enhanced selectivity and potency for fVIIa. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.040
• 作为产物：
  描述：

  2-(3-溴-5-甲酰基-4-((2-甲氧基乙氧基)甲氧基)苯基)琥珀酸二甲酯 在 tris(triphenylphosphano)palladium 、 对苯醌 作用下， 以 甲醇 、 乙二醇二甲醚 为溶剂， 生成 2-[5-(5-Carbamimidoyl-1H-benzoimidazol-2-yl)-6-(2-methoxy-ethoxymethoxy)-3'-nitro-biphenyl-3-yl]-succinic acid dimethyl ester
  参考文献：
  名称：

  Factor VIIa inhibitors: Improved pharmacokinetic parameters

  摘要：

  Efforts to improve the potency and pharmacokinetic properties of small molecule factor VIIa inhibitors are described. Small structural modifications to existing leads allow the modulation of half-life and clearance, potentially making these compounds suitable candidates for drug development. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.037